Here, the transcriptomics and metabolomics on a model
of exposure
to a cocktail of neonicotinoids (Neo) containing seven commercial
compounds and a synergist piperonyl butoxide (PBO) were established.
The results showed that Neo and PBO disrupted mRNA and metabolite
levels in a dose-dependent manner. Neo caused tryptophan pathway-related
neurotoxicity, reduced lipolysis, and promoted fat mass accumulation
in the liver, while PBO induced an increase in inflammatory factors
and damage to intercellular membranes. Co-exposure enhanced Neo-induced
liver steatosis, focal necrosis, and oxidative stress by inhibiting
oxidative phosphorylation (OXPHOS). Furthermore, diglycerides and
metabolic biomarkers demonstrated that the activation of insulin signaling
is associated with restricted OXPHOS, which commonly leads to a high
risk of non-alcoholic fatty liver disease (NAFLD) and Alzheimer’s
disease (AD) as the result of over-synthesis of lipids, low energy
supply, and high thermogenesis. The study demonstrates that chronic
disease can be induced by Neo and the synergist PBO at the molecular
level.